Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991
Conditions
Keywords
ASP7991, Plasma concentration, Pharmacodynamics, Pharmacokinetics
Brief summary
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
Detailed description
To examine the pharmacokinetics, pharmacodynamics and safety in patients with chronic kidney disease undergoing hemodialysis. * To assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and the effect of hemodialysis on PK of single oral administration of ASP7991 in Part 1. * To assess the safety, PK and PD of repeated oral administration of ASP7991 in part 2.
Interventions
DRUGASP7991
oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients on stable chronic maintenance dialysis who are receiving hemodialysis therapy 3 times/week for more than 12 weeks (84 days) and are also scheduled to undergo the regimen of 3 times/week hemodialysis during the study period * Patients who have secondary hyperparathyroidism; 1. Receiving Active vitamin D or Cinacalcet hydrochloride 2. OR iPTH values ≥ 180 pg/mL at screening in case patients receive no medication for secondary hyperparathyroidism. * Corrected serum Ca at screening：≥ 8.4 mg/dL * No changes in items below at least 7 days before screening and do not have a plan to change something in the items below during the trial. 1. Dose and type of Active Vitamin D, Calcitonin preparation, Phosphate binder. 2. Ca concentration of the dialysate, membrane area of the dialyzer and dialysis time of each week(possible to change within ±10%)
Exclusion criteria
* Patients who underwent parathyroid intervention within 24 weeks prior to the informed consent * Patients who have primary hyperparathyroidism * Having a history of gastric/intestinal resection considered influential on the absorption of the drug in the gastrointestinal tract * Patients with uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 120 mmHg are showed at the previous three points at the initiation of dialysis including the screening assessment) * Complicated by severe heart disorder \[congestive cardiac failure (NYHA classification III or higher), or wide range of old myocardial infarction\], or having a history of hospitalization for cerebro-vascular disease or heart disorder within 12 weeks(84 days) before obtaining the informed consent. * Concurrent serious hepatic disease (acute and active chronic hepatitis, hepatic cirrhosis) * History of malignant tumor * History of serious drug allergy including anaphylactic shock * Potentially child-bearing, lactating, those who do not comply with the instructed contraceptive measures * Patients who were involved in an assessment of other clinical trial within 12 weeks(84 days) prior to the informed consent * Patients who is an employee of the sponsor, CRO, SMO, or sites related to the study. * Patients who have been judged ineligible to participate in the study by the investigator / sub investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety of ASP7991 assessed by the incidence of adverse events, vital signs, laboratory tests, 12-lead ECGs, ECGs for QT evaluation and ophthalmic examination | For 9-16 days after dosing |
Secondary
| Measure | Time frame |
|---|---|
| Plasma concentrations unchanged drug; AUClast, AUCinf, AUC24h, Cmax, Ctrough, tmax, t1/2, CL/F, Vz/F | For 9-16 days after dosing |
| iPTH, wPTH, corrected serum Ca* (Serum Ca and Serum Alb), P | For 9-16 days after dosing |
Countries
Japan
Outcome results
None listed